Business Wire

CA-ULTRAVIOLET-DEVICES

12.10.2020 08:02:14 CEST | Business Wire | Press release

Share
UVDI Announces UV-C Device Presentations at the 16th World Congress on Public Health 2020

Ultraviolet Devices, Inc. (UVDI), a global leader in UV-C surface disinfecting and indoor air quality products, today announced its first Italian hospital studies demonstrating the advanced effectiveness of the UVDI-360 Room Sanitizer will be presented at the 16th World Congress on Public Health 2020, taking place October 12 – 16, 2020. The novel research, conducted by Dr. Gabriele Messina, Associate Professor of Public Health, University of Siena, at the Rugani Hospital Monteriggioni in Siena, demonstrates the UVDI-360’s ability to inactivate pathogens in the hospital environment as part of varied cleaning protocols, in multiple high-risk locations and at different disinfecting cycle times.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201011005076/en/

Presentations from Dr. Messina and his Team at the University of Siena include:

(1) one poster sharing preliminary data of a cross-sectional study measuring overall pathogen reduction on high-touch surfaces in hospital rooms pre-and-post use of the UVDI-360 Room Sanitizer as a supplement to terminal cleaning. Preliminary findings conclude 83% of sites sampled had 0 CFU following the use of the UVDI-360 Room Sanitizer.

(2) a second poster sharing preliminary data of a cross-sectional study demonstrating overall pathogen reduction in operating rooms in six minutes with the UVDI-360 Room Sanitizer used in multiple protocols: with no manual cleaning, manual cleaning in-between operating room use and as a supplement to manual terminal cleaning.

(3) an oral presentation sharing research demonstrating 3-and-4-log reductions of Candida auris at 2.44 meters using the UVDI-360 Room Sanitizer.

(4) a third poster illustrating a simulation model of microbe distribution on surfaces to inform future UV-C testing.

Title: Six ultraviolet minutes for cleaner operating theatres
Track:
Health Technology Assessment
Abstract: # DJ-15

Title: Analytical approach for a better control of environmental contamination
Track:
Hospital hygiene (including AMR), healthcare-associated infections (HAI)
Abstract: #DN-18

Title: A simulation model of microbe overlapping for the correct estimation of UV-C device log-reduction
Track:
Healthcare Technology Assessment
Abstract: # DJ-14

Oral Presentation: Tuning a UV-C device to challenge new threats in the sanitization setting of healthcare facilities
Date and Time:
October 13th , 12:15-13:15

Poster abstracts are accessible via the World Congress website, https://wcph2020.com/ . The poster presentations may be accessed through UVDI’s website following their presentation.

About UVDI

UVDI's Mission is to make a cleaner, safer, and healthier world through advanced UV-C solutions that disinfect the air and surfaces in the environments we live, work, and play in. Founded in 1949 by Louis Veloz, UVDI designs and makes next-generation germicidal Ultraviolet light solutions in California applying over 70 years and three generations of family craftsmanship and care. The UVDI-360 Room Sanitizer is now used globally in over 25 countries in the world’s leading hospitals, where it has been proven in peer-reviewed, published studies to reduce Healthcare-Associated Infections and inactivate the highest-risk pathogens. UVDI is proud to be a certified Minority Business Enterprise (MBE).

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Vertex Presents New Data on ALYFTREK® at European Cystic Fibrosis Conference5.6.2026 18:00:00 CEST | Press release

- ALYFTREK Phase 3 data on children with cystic fibrosis ages 2 to 5 with vanzacaftor/tezacaftor/deutivacaftor-responsive genotypes including F/F and F/MF shows 65% reached sweat chloride levels of <30 mmol/L; Vertex on track to initiate global regulatory submissions in first half of 2026 - - Long-term 96-week interim analyses from two open-label extension studies demonstrate positive safety and efficacy profile of ALYFTREK in people with cystic fibrosis ages 6 and older -- Phase 3 data on TRIKAFTA® in children 1 to <2 years also presented; Vertex has initiated global regulatory submissions - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data demonstrating the potentially transformative impact of treating cystic fibrosis (CF) with ALYFTREK ® (vanzacaftor/tezacaftor/deutivacaftor) in children ages 2 to 5, as well as data from 96-week interim analyses of two open-label extension studies of ALYFTREK in children 6 to 11 years and people 12 years and older demonstrating

Owkin to Build AI Agents as Part of a Multi-Year K Pro Collaboration with Sanofi5.6.2026 13:00:00 CEST | Press release

Owkin, the agentic AI company pioneering Biological Artificial Superintelligence to transform drug discovery and development, today announced a multi-year collaboration with Sanofi to co-develop next-generation biopharma agents, to be backed by a five-year license for K Pro, Owkin’s AI Scientist. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260605704506/en/ K Pro, Owkin's AI scientist for biology, powered by multimodal patient data for smarter biopharma decision making. Owkin and Sanofi have collaborated since 2021 through a €90 million strategic partnership focused on target identification in oncology and patient subgrouping. The collaboration was later expanded to include drug positioning for Sanofi’s immunology pipeline. This new collaboration represents the next evolution in the partnership. During the five-year collaboration, Owkin will lead the end-to-end development of novel AI-driven biopharma agents purpose-built

DFNS Rebrands as the Core Banking Platform for Digital Assets5.6.2026 12:41:00 CEST | Press release

DFNS today announced a rebrand, marking its evolution from a wallet infrastructure to the first core banking platform for digital assets. The company is introducing a new logo, website, and market position as fintechs and institutions move their products and operations onchain. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260603859127/en/ Banks, fintechs, asset managers, trading firms, payment providers, market infrastructures, and clearing houses have stopped asking how to "add crypto." They're asking how to run financial products, controls, workflows, and client services on blockchain rails, with the reliability expected of core infrastructure. Some are going further still, exploring whether the blockchain can serve as the ledger itself, where an account is an onchain object rather than a row in a database. Where IBANs, virtual accounts, and blockchain wallets converge into one governed financial account. “DFNS was built

Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.6.2026 12:30:00 CEST | Press release

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to seventeen newly hired non-executive employees. The equity awards were granted on June 1, 2026 and consisted of options to purchase an aggregate of 157,000 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 74,700 shares. The options have an exercise price per share equal to $14.19, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restrict

Renewable Electricity, Soft Wheat Flour From Regenerative Agriculture, Initiatives to Support Local Communities: Barilla Shares These and Other Projects in “Stories of Sustainability.”5.6.2026 10:00:00 CEST | Press release

Barilla continues to advance its commitment to tastier products with less sugar and salt;An investment of 30 million euros in 2025 to quadruple photovoltaic capacity across plants, as part of a €168 million five-year plan focused on energy efficiency, renewable energy and sustainable water management.Barilla continues to expand regenerative agriculture practices across its global value chain, with over 816,000 tons of raw materials sourced through the Barilla Sustainable Farming program.4,000 tons of products donated worldwide and €2 million allocated to social causes in 2025, supporting communities across Barilla’s global footprint through food donations and social initiatives. A slimmer Tagliatelle pack that saves 150 tons of cardboard and cuts transport-related CO₂ emissions by 20%1; ready-made sauce jars made with around 65% recycled glass; the progressive scaling of regenerative agriculture practices across Barilla’s value chain and initiatives supporting inclusion and equal oppor

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye